Browse evidence-based analysis of health-related claims and assertions
When these young women feel more depressed, they also tend to feel more scared of the war, more emotionally drained, and more alone — and their depression is the biggest factor linked to feeling burned out.
Correlational
Where in the liver insulin resistance happens determines whether it causes high blood sugar, high fat, or neither.
Descriptive
The front part of the liver needs insulin to handle sugar properly when eating a high-fat diet—without it, blood sugar rises.
Mechanistic
Insulin signals in the back part of the liver help fat build up there when the mouse eats a high-fat diet.
When insulin doesn’t work in the back part of the liver, the body doesn’t respond by making more insulin—even though fat in the liver goes down.
Even if you block insulin in the front part of the liver, the mouse still gets high blood sugar when eating a high-fat diet.
When mice eat a high-fat diet, fat builds up in both parts of the liver—but blocking insulin in just one part stops fat from building up there.
Turning off insulin signals in the back part of the liver cuts fat without making the body pump out more insulin.
The liver isn’t the same all the way through—different parts react differently when insulin stops working, leading to very different outcomes for fat and sugar.
When the front part of the liver can't respond to insulin, blood sugar goes up—even if the liver makes less fat.
When the front part of the liver doesn’t respond to insulin, the body makes more insulin to try to compensate.
Turning off insulin signals in the back part of the liver doesn’t make blood sugar go up, even when the mouse eats a high-fat diet.
The front part of the liver needs insulin to make fat when the mouse eats a lot of fat—without it, fat production drops.
When insulin doesn't work in the back part of the liver, the muscles start using more sugar instead, which helps keep blood sugar levels normal.
Blocking insulin signals in the other part of the liver (pericentral zone) cuts down fat buildup in that area without raising blood sugar, even when the mouse eats a high-fat diet.
When the part of the liver that usually responds to insulin is blocked, the liver makes less fat even when the mouse eats a high-fat diet—but its blood sugar and insulin go up instead.
Combinatorial targeting of adipose tissue mobilization (via GHRH/IGF-1) and mitochondrial fuel utilization (via AMPK) produces synergistic metabolic benefits beyond additive effects.
Assertion
MOTS-c activates AMP-activated protein kinase (AMPK), leading to improved glucose uptake, insulin sensitivity, and metabolic efficiency independent of growth hormone signaling.
Tesamorelin upregulates nuclear-encoded genes involved in mitochondrial oxidative phosphorylation and fatty acid β-oxidation.
Increased IGF-1 levels are associated with enhanced mitochondrial oxidative capacity, as measured by phosphocreatine recovery kinetics following exercise.
Tesamorelin increases cross-sectional area and density of trunk skeletal muscles while reducing intramyocellular lipid infiltration.
Reduction in adipose tissue volume is accompanied by increased adipocyte density, reflecting smaller adipocyte size, improved vascularization, reduced hypoxia, and decreased local inflammation.
Hepatic lipid accumulation impairs insulin signaling and glucose metabolism, acting as a primary driver of systemic insulin resistance.
Administration of tesamorelin results in a statistically significant reduction in visceral adipose tissue volume compared to placebo, with a mean reduction of approximately 11% after 6 months of treatment.
Quantitative